Editorial: Update on the Biology, Management, and Treatment of Small Cell Lung Cancer.
作者信息
Puri Sonam, Lok Benjamin H, Leighl Natasha, Gray Jhanelle E
机构信息
Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States.
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
出版信息
Front Oncol. 2020 Nov 17;10:1783. doi: 10.3389/fonc.2020.01783. eCollection 2020.
Abstract
摘要
相似文献
1
Editorial: Update on the Biology, Management, and Treatment of Small Cell Lung Cancer.
Front Oncol. 2020 Nov 17;10:1783. doi: 10.3389/fonc.2020.01783. eCollection 2020.
2
Editorial: Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine.
Front Oncol. 2017 Dec 13;7:311. doi: 10.3389/fonc.2017.00311. eCollection 2017.
3
Small-cell lung cancer: an update on targeted therapies.
Adv Exp Med Biol. 2013;779:385-404. doi: 10.1007/978-1-4614-6176-0_18.
4
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
JAMA. 2019 Aug 27;322(8):764-774. doi: 10.1001/jama.2019.11058.
5
[Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
Klin Onkol. 2016 Fall;29 Suppl 4(Suppl 4):78-87.
6
Combining Immunotherapy with Radiation Therapy in Non-Small Cell Lung Cancer.
Thorac Surg Clin. 2020 May;30(2):221-239. doi: 10.1016/j.thorsurg.2020.01.002. Epub 2020 Mar 2.
7
Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.
Semin Cancer Biol. 2018 Oct;52(Pt 1):103-109. doi: 10.1016/j.semcancer.2017.11.019. Epub 2017 Nov 26.
8
Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?
Int J Mol Sci. 2018 Dec 21;20(1):24. doi: 10.3390/ijms20010024.
9
Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer.
Radiol Clin North Am. 2018 May;56(3):485-495. doi: 10.1016/j.rcl.2018.01.012.
10
Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.
Curr Cancer Drug Targets. 2019;19(8):595-630. doi: 10.2174/1568009619666181210114559.
引用本文的文献
1
The effects of surgical resection in the treatment of limited-stage small cell lung cancer: a multicenter retrospective study.
Updates Surg. 2024 Aug;76(4):1483-1492. doi: 10.1007/s13304-023-01708-z. Epub 2023 Dec 3.
本文引用的文献
1
Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.
Front Oncol. 2020 Jun 25;10:1079. doi: 10.3389/fonc.2020.01079. eCollection 2020.
2
Targeted Therapies and Biomarkers in Small Cell Lung Cancer.
Front Oncol. 2020 May 20;10:741. doi: 10.3389/fonc.2020.00741. eCollection 2020.
3
A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials.
Front Oncol. 2020 Jan 8;9:1460. doi: 10.3389/fonc.2019.01460. eCollection 2019.
4
Cancer statistics, 2020.
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
5
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses.
J Thorac Oncol. 2020 Feb;15(2):274-287. doi: 10.1016/j.jtho.2019.10.013. Epub 2019 Oct 23.
6
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.
7
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.
Nat Rev Cancer. 2019 May;19(5):289-297. doi: 10.1038/s41568-019-0133-9.
8
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25.
9
Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers.
Cell Metab. 2018 Sep 4;28(3):369-382.e5. doi: 10.1016/j.cmet.2018.06.005. Epub 2018 Jun 28.
10
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.
Cancer Cell. 2017 Feb 13;31(2):270-285. doi: 10.1016/j.ccell.2016.12.005. Epub 2017 Jan 12.
Zotero 插件